A Rare Disease Overview of IC-MPGN and C3G

Rare kidney diseases have a special talent for sounding like alphabet soup and behaving like unwanted plot twists. Two of the most confusing names in that category are immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G). They can look alike in the clinic, overlap on kidney biopsy, and cause many of the same symptoms, yet they are not the same disease. That distinction matters, because the difference can shape how doctors search for triggers, monitor progression, and choose treatment.

At their core, both conditions damage the glomeruli, the tiny kidney filters that are supposed to quietly clean the blood all day without asking for applause. When those filters are injured, blood and protein can leak into the urine, fluid can build up, blood pressure can rise, and kidney function can slowly or sometimes quickly worsen. In short, the kidneys stop acting like precise filtration systems and start behaving more like overworked coffee filters on a Monday morning.

What Are IC-MPGN and C3G?

IC-MPGN is a rare form of glomerular disease in which immune complexes build up in the kidneys and trigger inflammation. These immune complexes are clusters formed when antibodies bind to substances the body sees as harmful. Once they settle into the glomeruli, they can activate parts of the immune system and damage the kidney’s filtering structures.

C3G, on the other hand, is a rare kidney disease driven mainly by dysregulation of the complement system, especially the alternative pathway. The complement system is part of the immune system, but in C3G it becomes overactive and leaves behind too much C3-related material in the kidneys. Instead of helping defend the body, it ends up causing collateral damage where nobody asked for fireworks.

C3G is not one single entity. It includes two major subtypes:

1. Dense Deposit Disease (DDD)

This subtype is identified by very dense deposits seen on electron microscopy. It is often diagnosed in younger patients and has long been one of the classic examples of complement-driven kidney injury.

2. C3 Glomerulonephritis (C3GN)

This subtype also features dominant C3 deposition, but the ultrastructural pattern differs from DDD. The name sounds a little less dramatic than “dense deposit disease,” but it is no less serious.

Why These Diseases Are Often Confused

Historically, both IC-MPGN and C3G were grouped under older biopsy-based categories of membranoproliferative glomerulonephritis. Today, specialists focus more on what is driving the damage rather than only what the kidney tissue looks like under the microscope. That shift is important. A similar biopsy pattern can come from different mechanisms, and when the mechanism changes, treatment strategy may change too.

In plain English: two people can have kidney biopsies that look like cousins, while the actual disease process is more like distant relatives who only meet at awkward holidays.

IC-MPGN vs. C3G: The Key Difference

The simplest way to separate them is this:

• IC-MPGN is driven mainly by immune complexes, though complement activation can also contribute.
• C3G is driven mainly by abnormal complement activity, especially overactivation involving C3.

That distinction is often confirmed by kidney biopsy, especially with immunofluorescence and electron microscopy. In C3G, the biopsy shows dominant C3 staining. In IC-MPGN, immune complexes and immunoglobulins are more central to the picture. Because these diseases are rare and technically tricky, the biopsy should ideally be reviewed by experts familiar with glomerular disease.

What Causes IC-MPGN?

IC-MPGN can develop when chronic immune activity keeps creating damaging immune complexes. In some patients, it is associated with long-term infections, autoimmune diseases, or certain cancers. In others, no clear trigger is found, and the disease may be labeled primary or idiopathic.

This matters because treatment is not just about calming kidney inflammation. It may also require finding and managing the underlying driver. If a chronic infection or autoimmune condition is fueling the process, ignoring that trigger is like trying to mop the floor while the faucet is still running.

What Causes C3G?

C3G is linked to abnormal control of the complement system. This may happen because of genetic variants, autoantibodies, or both. Some patients have complement-related autoantibodies such as C3 nephritic factors, which help keep the alternative pathway switched on longer than it should be. Others have abnormalities in complement-regulating proteins such as factor H, factor I, factor B, or related pathways.

Not every case of C3G is inherited in a simple way, and not every patient will have a single easy-to-point-at cause. That is one reason diagnosis often includes more than a biopsy. Doctors may also use blood work, complement testing, genetic testing, and a broader search for acquired triggers.

Common Signs and Symptoms

Both IC-MPGN and C3G can be sneaky at first. Some patients are diagnosed only after routine urine testing finds blood or protein. Others show up with symptoms that are much harder to ignore.

Symptoms that often appear in both diseases

• Blood in the urine that may be visible or microscopic
• Protein in the urine, sometimes causing foamy urine
• Swelling in the face, around the eyes, hands, legs, or feet
• High blood pressure
• Fatigue and reduced concentration
• Reduced kidney function, sometimes progressing to chronic kidney disease

C3G can also come with a few extra plot points, including low C3 levels, drusen in the eyes, and in some patients acquired partial lipodystrophy. Not everyone develops these features, but when they appear they can help reinforce that the disease is more than a simple kidney-only problem.

How Doctors Diagnose IC-MPGN and C3G

Diagnosis usually starts with clues from everyday kidney testing: abnormal urine protein, hematuria, rising creatinine, swelling, or hypertension. But the real detective work often begins after that.

Tests commonly used

• Urinalysis to look for blood and protein
• Blood tests to evaluate kidney function and complement levels
• Kidney biopsy to define the pattern of injury
• Immunofluorescence to identify C3 and immunoglobulin staining
• Electron microscopy to distinguish DDD from C3GN and refine diagnosis
• Complement workup and genetic testing in selected cases
• Evaluation for secondary causes, especially in IC-MPGN

That last step is crucial. In IC-MPGN, physicians may search for hidden infections, autoimmune disease, or other systemic problems. In C3G, they may dig deeper into complement biology. This is one reason many patients benefit from a multidisciplinary care team that can include nephrologists, nephropathologists, primary care clinicians, and sometimes genetic or immunology specialists.

How Serious Are These Diseases?

Unfortunately, both IC-MPGN and C3G can be progressive. Some patients remain stable for years with close monitoring and supportive care. Others move more quickly toward chronic kidney disease, dialysis, or kidney transplant. C3G is especially known for having a significant risk of kidney failure over time, and recurrence after transplant can also be a concern.

That does not mean every patient follows the same script. Far from it. Disease severity can vary based on age, biopsy findings, degree of proteinuria, response to treatment, underlying triggers, and how early the disease is identified. Rare disease medicine is rarely neat. It is more like a puzzle where some pieces arrive late and a few are upside down.

Treatment: What Care Looks Like Today

Treatment still begins with the basics, because the basics matter. Supportive kidney-protective care is often the foundation for both IC-MPGN and C3G.

Supportive care may include

• Blood pressure control
• RAAS blockade, such as ACE inhibitors or ARBs, to reduce proteinuria
• Dietary sodium management
• Treatment of swelling, cholesterol issues, or related complications
• Close monitoring of kidney function and urine protein

For years, many patients also received immunosuppressive therapy, especially when inflammation appeared more active or when kidney specialists judged the disease moderate to severe. Drugs such as corticosteroids and mycophenolate mofetil have been used in selected cases, particularly in complement-mediated disease when older guideline-based strategies were applied.

What is new in the treatment landscape?

This is where the story has changed in a meaningful way. In March 2025, the FDA approved iptacopan for adults with C3G to reduce proteinuria. Then in July 2025, the FDA approved pegcetacoplan for patients 12 years and older with C3G or primary IC-MPGN to reduce proteinuria. Those approvals marked a major shift from the old era of “we mostly support and hope for the best” toward more targeted complement-focused therapy.

That said, newer approval does not mean one-size-fits-all care. Doctors still need to consider age, biopsy findings, transplant history, infection risk, kidney function, insurance access, and whether the disease is primary or secondary. In IC-MPGN, identifying and treating a root cause can still be just as important as choosing a kidney-specific medication.

Living With a Rare Kidney Disease

Living with IC-MPGN or C3G can be exhausting in ways lab reports do not fully capture. Rare diseases often come with delayed diagnosis, repeated testing, specialist visits, insurance paperwork, and the strange loneliness of having a condition most people cannot pronounce. Even some clinicians may not see these diseases often, which means patients and families sometimes end up becoming expert-level translators of their own medical story.

Practical self-management usually includes staying on top of lab monitoring, taking medications consistently, managing salt intake when advised, tracking swelling or blood pressure changes, and keeping follow-up appointments even when symptoms seem quiet. Quiet disease is not always harmless disease. The kidneys can lose ground politely and without much noise.

Why Awareness Matters

IC-MPGN and C3G are rare, but rarity should never be mistaken for insignificance. These are serious diseases that can affect children, teens, and adults. They can disrupt school, work, pregnancy planning, family life, mental health, and long-term financial stability. Better awareness helps people reach nephrology care sooner, get more accurate biopsies, and ask smarter questions about complement testing, treatment options, and clinical trials.

The best summary may be this: IC-MPGN and C3G may look similar, but they are not interchangeable. IC-MPGN leans more toward immune complex injury, while C3G centers on complement dysregulation. Understanding that difference is not academic trivia. It is the map that guides better diagnosis, more precise care, and a little more hope than patients had just a few years ago.

Experiences Related to IC-MPGN and C3G

For many patients, the experience of living with IC-MPGN or C3G begins long before the diagnosis actually gets a name. Someone may notice puffy eyes in the morning, ankles that suddenly seem determined to become balloons by evening, or urine that looks strangely foamy. A teenager might hear that a routine school physical found blood in the urine. An adult might learn after “just a little swelling” that their blood pressure is high and kidney function is slipping. Rare disease often enters the room quietly, then takes over the conversation.

One common experience is diagnostic whiplash. Patients are often told at first that the problem may be a urinary tract issue, dehydration, stress, or “probably nothing serious.” Then comes more blood work, a referral to nephrology, more waiting, and finally a kidney biopsy. That biopsy can feel emotionally huge. Even when people understand why it is needed, the procedure often marks the moment when a vague worry turns into something real. Suddenly the medical language gets dense, the acronyms get longer, and life becomes measured in creatinine, proteinuria, C3 levels, and follow-up appointments.

Another shared experience is the uncertainty of unpredictability. Some patients feel mostly normal but have abnormal labs. Others feel tired all the time, battle swelling, and struggle to keep up with school, work, parenting, or exercise. Many describe a strange mismatch between how sick they look and how sick they feel. On the outside, they may appear fine. On the inside, they may be carrying fatigue, anxiety, and the constant background worry that the next set of labs will go in the wrong direction.

Families often experience their own version of the disease. Parents of children with C3G may become accidental experts in lab reports, insurance appeals, and medication schedules. Partners of adults with IC-MPGN may learn how to recognize swelling before the patient does. Caregivers often juggle practical tasks with emotional support, which is a lot to carry when the disease itself is rare and unfamiliar.

Patients also talk about the emotional weight of hearing words like dialysis, transplant, or recurrence. Even if those outcomes are not immediate, just knowing they are possible can change how someone thinks about the future. Plans around college, careers, pregnancy, travel, and finances can suddenly feel more complicated. Rare disease does not just affect the kidneys. It can rearrange a person’s sense of time.

And yet, there is also a different kind of experience that deserves space: adaptation. Many patients learn how to advocate for themselves, keep excellent records, ask better questions, and build strong relationships with their care teams. Some find comfort in rare-disease communities where they no longer need to explain what C3G or IC-MPGN means. Others describe relief simply from having an accurate diagnosis after months or years of confusion. A difficult name, oddly enough, can still bring clarity.

That may be one of the most human truths about IC-MPGN and C3G. The diseases are medically complex, but the experience is deeply personal. It is about more than complement pathways and biopsy stains. It is about trying to live an ordinary life while carrying an extraordinary diagnosis, and learning, one appointment at a time, that knowledge can be scary but it can also be power.

Conclusion

IC-MPGN and C3G are rare kidney diseases with overlapping symptoms but different biological drivers. IC-MPGN is more closely tied to immune complex injury, while C3G is defined by abnormal complement activity and dominant C3 deposition in the kidneys. Both can lead to serious kidney damage, but advances in diagnosis and targeted therapy are making the picture less bleak than it used to be. The sooner patients reach expert care, the better the odds of getting the right tests, the right treatment plan, and a clearer path forward.